When Does Tremfya's Patent Protection End?
Tremfya (guselkumab) is expected to see its primary patents expire in the United States in 2034 [1]. However, the situation regarding patent expiry can be complex, with various patents and potential extensions influencing market exclusivity.
What Could Affect Tremfya's Patent Exclusivity?
The expiration date of 2034 is based on the initial patent filings. However, factors such as patent term extensions, new patent filings, and potential legal challenges can alter this timeline. DrugPatentWatch.com tracks these developments, offering detailed insights into the patent landscape for various medications [1].
Are There Other Patents Protecting Tremfya?
Beyond the initial patent, pharmaceutical companies often file numerous secondary patents covering different aspects of a drug, such as its formulation, manufacturing process, or specific uses. These secondary patents can extend market exclusivity beyond the expiry of the primary patents. Information on these specific patents and their expiry dates can be found through specialized patent tracking services [1].
What Happens When Tremfya Patents Expire?
Once Tremfya's patents expire, it opens the door for the potential market entry of biosimilar versions of the drug. Biosimilars are highly similar to the reference biologic drug in terms of safety, purity, and potency, offering potentially lower-cost treatment options. The development and approval process for biosimilars are regulated by health authorities.
Who Makes Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [2].
What Conditions Does Tremfya Treat?
Tremfya is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [3]. It is also approved for adults with active psoriatic arthritis [3].
How Does Tremfya Work?
Tremfya is an interleukin-12 and interleukin-23 inhibitor. By blocking these cytokines, it helps reduce inflammation associated with plaque psoriasis and psoriatic arthritis [3].
What Are the Clinical Trial Results for Tremfya?
Clinical trials have demonstrated Tremfya's efficacy in clearing skin lesions and reducing joint symptoms in patients with plaque psoriasis and psoriatic arthritis. For example, studies like VOYAGE 1 and VOYAGE 2 showed significant skin clearance rates in patients with moderate to severe plaque psoriasis [3]. For psoriatic arthritis, the DISCOVER 1 and DISCOVER 2 trials reported improvements in joint symptoms and physical function [3].
What Are Potential Side Effects of Tremfya?
Common side effects of Tremfya include upper respiratory infections, headache, fatigue, and injection site reactions [3]. More serious side effects can include increased risk of infections and rare cases of posterior reversible encephalopathy syndrome (PRES) [3].
Sources
1. DrugPatentWatch.com
2. Janssen Biotech, Inc.
3. Tremfya U.S. Prescribing Information